Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

• Status: Active, not recruiting
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break whereby main reasons for not quitting or relapsing after cessation are the nicotine withdrawal syndrome and post-cessational weight gain. GLP-1 analogues are well known to stimulate insulin secretion and to reduce energy intake and therefore body weight. Recent findings from animal and human studies suggest a role of GLP-1 in the pathophysiology of addiction. The putative role of GLP-1 analogues in nicotine reward regulation combined with its weight reducing effects might be of major interest in view of novel pharmacotherapeutic options for smoking cessation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Dulaglutide; Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Age 18 to 75 years

• Daily smokers who are willing to quit and exhibit one of the following criteria: ≥10 cigarettes per day or

• At least moderate nicotine dependence defined by a Fagerstroem Score of ≥5 Points or

• Tobacco associated disease Treatment with varenicline (Champix®)

Exclusion Criteria:

• Pregnancy (incl. wish to become pregnant within next 3 months) or breast feeding

• Pre-existing Treatment with GLP-1 agonists

• History of pancreatitis

• Severe renal insufficiency (estimated glomerular Filtration rate smaller than 30 ml/min/1.73 m2)

• Instable psychiatric conditions

• Anorexia nervosa